The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease (original) (raw)

• Lees, A. J., Hardy, J. & Revesz, T. Parkinson's disease. Lancet 373, 2055–2066 (2009).
  Article CAS PubMed Google Scholar
• Gasser, T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. Med. 11, e22 (2009).
  Article PubMed Google Scholar
• Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genet. 41, 1303–1307 (2009).
  Article CAS PubMed Google Scholar
• Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genet. 41, 1308–1312 (2009).
  Article CAS PubMed Google Scholar
• Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595–600 (2004).
  Article CAS PubMed Google Scholar
• Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004).
  Article CAS PubMed Google Scholar
• Greggio, E. et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283, 16906–16914 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Greggio, E. et al. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 389, 449–454 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kamikawaji, S., Ito, G. & Iwatsubo, T. Identification of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963–10975 (2009).
  Article CAS PubMed Google Scholar
• Klein, C. L. et al. Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem. 111, 703–715 (2009).
  Article CAS PubMed Google Scholar
• Berger, Z., Smith, K. A. & Lavoie, M. J. Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49, 5511–5523 (2010).
  Article CAS PubMed Google Scholar
• Gloeckner, C. J. et al. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J. Proteome Res. 9, 1738–1745 (2010).
  Article CAS PubMed Google Scholar
• Dzamko, N. et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem. J. 430, 405–413 (2010).
  Article CAS PubMed Google Scholar
• Gehrke, S., Imai, Y., Sokol, N. & Lu, B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637–641 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Y. et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neurosci. 12, 1826–1828 (2009).
  Google Scholar
• Lin, X. et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant α-synuclein. Neuron 64, 807–827 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tong, Y. et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA 107, 9879–9884 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, B. D. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Med. 16, 998–1000 (2010).
  Article CAS PubMed Google Scholar
• Li, X. et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 30, 1788–1797 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Melrose, H. L. et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 40, 503–517 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Galter, D. et al. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59, 714–719 (2006).
  Article CAS PubMed Google Scholar
• Guo, L. et al. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658–3670 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Lewis, P. A. et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 1668–1671 (2007).
  Article Google Scholar
• Greggio, E. et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329–341 (2006).
  Article CAS PubMed Google Scholar
• Jaleel, M. et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307–317 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Nichols, R. J. et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem. J. 430, 393–404 (2010).
  Article CAS PubMed Google Scholar
• West, A. B. et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842–16847 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Imai, Y. et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432–2443 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Greggio, E. & Cookson, M. R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1, e00002 (2009).
  Article PubMed PubMed Central Google Scholar
• Lu, B. et al. Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2. Biochim. Biophys. Acta 1804, 1780–1784 (2010).
  Article CAS PubMed Google Scholar
• Sen, S., Webber, P. J. & West, A. B. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem. 284, 36346–36356 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, M., Dobson, B., Glicksman, M. A., Yue, Z. & Stein, R. L. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Biochemistry 49, 2008–2017 (2010).
  Article CAS PubMed Google Scholar
• Smith, W. W. et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neurosci. 9, 1231–1233 (2006).
  Article CAS PubMed Google Scholar
• Cookson, M. R., Hardy, J. & Lewis, P. A. Genetic neuropathology of Parkinson's disease. Int. J. Clin. Exp. Pathol. 1, 217–231 (2008).
  CAS PubMed PubMed Central Google Scholar
• Gandhi, P. N., Wang, X., Zhu, X., Chen, S. G. & Wilson-Delfosse, A. L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86, 1711–1720 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gillardon, F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-β isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J. Neurochem. 110, 1514–1522 (2009).
  Article CAS PubMed Google Scholar
• Sancho, R. M., Law, B. M. & Harvey, K. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet. 18, 3955–3968 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ding, X. & Goldberg, M. S. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS ONE 4, e5949 (2009).
  Article PubMed PubMed Central Google Scholar
• Ko, H. S. et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc. Natl Acad. Sci. USA 106, 2897–2902 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hsu, C. H. et al. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem. 112, 1593–1604 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Jorgensen, N. D. et al. The WD40 domain is required for LRRK2 neurotoxicity. PLoS ONE 4, e8463 (2009).
  Article PubMed PubMed Central Google Scholar
• MacLeod, D. et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587–593 (2006).
  Article CAS PubMed Google Scholar
• Parisiadou, L. et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29, 13971–13980 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Plowey, E. D., Cherra, S. J., Liu, Y. J. & Chu, C. T. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY2015Y cells. J. Neurochem. 105, 1048–1056 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sakaguchi-Nakashima, A., Meir, J. Y., Jin, Y., Matsumoto, K. & Hisamoto, N. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 17, 592–598 (2007).
  Article CAS PubMed Google Scholar
• Samann, J. et al. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284, 16482–16491 (2009).
  Article PubMed PubMed Central Google Scholar
• Tain, L. S. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nature Neurosci. 12, 1129–1135 (2009).
  Article CAS PubMed Google Scholar
• Kapahi, P. et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 11, 453–465 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hands, S. L., Proud, C. G. & Wyttenbach, A. mTOR's role in ageing: protein synthesis or autophagy? Aging 1, 586–597 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kumar, A. et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS ONE 5, e8730 (2010).
  Article PubMed PubMed Central Google Scholar
• Wider, C., Dickson, D. W. & Wszolek, Z. K. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener. Dis. 7, 175–179 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Taymans, J. M. & Cookson, M. R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, α-synuclein, and tau. Bioessays 32, 227–235 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Cookson, M. R. α-Synuclein and neuronal cell death. Mol. Neurodegener. 4, 9 (2009).
  Article PubMed PubMed Central Google Scholar
• Auluck, P. K., Caraveo, G. & Lindquist, S. α-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 26, 211–233 (2010).
  Article CAS PubMed Google Scholar
• Biskup, S. et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60, 557–569 (2006).
  Article CAS PubMed Google Scholar
• Rajput, A. et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506–1508 (2006).
  Article CAS PubMed Google Scholar
• Matenia, D. & Mandelkow, E. M. The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem. Sci. 34, 332–342 (2009).
  Article CAS PubMed Google Scholar
• Burre, J. et al. α-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663–1667 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Conde, C. & Caceres, A. Microtubule assembly, organization and dynamics in axons and dendrites. Nature Rev. Neurosci. 10, 319–332 (2009).
  Article CAS Google Scholar
• Kubo, M. et al. LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation. J. Neuroimmunol. 20 Aug 2010 (doi:10.1016/j.jneuroim.2010.07.021).
  Article CAS PubMed Google Scholar
• Nichols, R. J. et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J. 424, 47–60 (2009).
  Article CAS PubMed Google Scholar
• Haugarvoll, K. & Wszolek, Z. K. Clinical features of LRRK2 parkinsonism. Parkinsonism Relat. Disord. 15 (Suppl. 3), S205–S208 (2009).
  Article PubMed Google Scholar
• Funayama, M. et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301 (2002).
  Article CAS PubMed Google Scholar
• Funayama, M. et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57, 918–921 (2005).
  Article CAS PubMed Google Scholar
• Di Fonzo, A. et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412–415 (2005).
  Article CAS PubMed Google Scholar
• Gilks, W. P. et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415–416 (2005).
  CAS PubMed Google Scholar
• Kachergus, J. et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672–680 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Lesage, S. et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 2422–2423 (2006).
  Article Google Scholar
• Nichols, W. C. et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365, 410–412 (2005).
  CAS PubMed Google Scholar
• Ozelius, L. J. et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 2424–2425 (2006).
  Article Google Scholar
• Ishihara, L. et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch. Neurol. 63, 1250–1254 (2006).
  Article PubMed Google Scholar
• Kumari, U. & Tan, E. K. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J. 276, 6455–6463 (2009).
  Article CAS PubMed Google Scholar
• Halliday, G. M. & McCann, H. The progression of pathology in Parkinson's disease. Ann. NY Acad. Sci. 1184, 188–195 (2010).
  Article PubMed Google Scholar
• Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).
  Article PubMed Google Scholar